Aetna Begins Coverage of CardioDx's Coronary Artery Disease Test | GenomeWeb

NEW YORK (GenomeWeb) – CardioDx today announced that Aetna has established a clinical policy for the Corus CAD gene expression test for coronary artery disease.

As a result, members of Aetna and Coventry Health Care will have access to the test. According to Aetna's website, it serves about 44 million lives. Coventry, which Aetna acquired in 2013, has about 5 million members. CardioDx said that Aetna considers the test medically necessary for evaluating non-diabetic adults with chest pain or anginal equivalent symptoms but who have no prior history of obstructive CAD.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former NIH program officer says the Internet has blasted open the door for scientific publications more interested in dollars than quality research.

This Week in Science: New research into the emergence of infectious diseases, and scientists report on proteins involved in melanoma.

The hashtag #stupidcommonnames is gaining fans among scientists who find the common names of animals and plants dumb.

Fed up with budget slashes, job cuts, and muzzling mandates, researchers in Canada are making science a campaign issue in the upcoming elections.

Sep
17
Sponsored by
Omicia

This online seminar will provide examples of how commercial and hospital-affiliated clinical labs are successfully developing and deploying high-throughput next-generation sequencing-based testing services for genetic diseases. 

Oct
15
Sponsored by
Parabase

This webinar will discuss the benefits of a rapid targeted next-generation sequencing (TNGS) panel, using dried blood spots, for second-tier newborn metabolic and hearing loss screening and its immediate utility for high-risk diagnostic testing in the neonatal intensive care unit. 

Oct
29
Sponsored by
Lucigen

This webinar will focus on a range of research and clinical applications enabled by improvements in mate pair technology for whole genome sequencing.